Glyburide is a second-generation sulfonylurea that lowers A1C by 1 to 1.5 percent by triggering insulin release from the pancreas. It works well for blood sugar but carries more hypoglycemia risk than other drugs in its class because its metabolites linger. The Beers criteria flag glyburide as potentially inappropriate in adults 65 and over, and it should be avoided in kidney disease. It remains useful in select cost-constrained situations but is being phased out of routine US practice in favor of glipizide, glimepiride, or newer drug classes.
How Glyburide Works
Like all sulfonylureas, glyburide binds the SUR1 receptor on pancreatic beta cells. This closes ATP-sensitive potassium channels, depolarizing the cell, opening calcium channels, and pushing the cell to secrete insulin. The defining feature of the entire class — and the source of hypoglycemia — is that this stimulation happens whether or not blood glucose is elevated.
- Drug class: second-generation sulfonylurea
- Brand names: DiaBeta, Micronase (both discontinued in the US), Glynase (micronized)
- Outside the US: known as glibenclamide
- Generic status: yes, widely available
- Half-life: 4 hours for parent drug, but active metabolites persist much longer
- Excretion: roughly 50 percent renal, 50 percent biliary
Approved Uses
- Adjunct to diet and exercise in adults with type 2 diabetes
- Often combined with metformin (fixed-dose product: Glucovance)
- Historically used in gestational diabetes (now lower preference behind insulin)
- Not used for type 1 diabetes or diabetic ketoacidosis
Typical Dosing
| Formulation | Starting Dose | Maximum Dose | Timing |
|---|---|---|---|
| Glyburide (non-micronized) | 2.5 to 5 mg once daily | 20 mg/day | With breakfast; split if >10 mg/day |
| Glyburide micronized (Glynase) | 1.5 to 3 mg once daily | 12 mg/day | With breakfast; split if >6 mg/day |
| Older adults | 1.25 mg or 0.75 mg micronized | Titrate very slowly | With breakfast |
Dose titration is gradual — 1.25 to 2.5 mg every 1 to 2 weeks based on fasting glucose. Many clinicians prefer to switch to glipizide or glimepiride rather than push glyburide above 10 mg per day because hypoglycemia rates climb steeply.
Effects on A1C
- A1C reduction: 1.0 to 1.5 percent at peak
- Fasting glucose: 30 to 60 mg/dL reduction
- Peak effect: by 8 to 12 weeks
- Secondary failure: documented in long-term trials; the ADOPT trial showed sulfonylureas had higher rates of A1C escape at 5 years than metformin or rosiglitazone
Common Side Effects
- Hypoglycemia — more frequent and longer-lasting than with glipizide; symptoms include sweating, shakiness, hunger, confusion, palpitations
- Weight gain — 3 to 5 kg over the first year
- Nausea, fullness, heartburn
- Headache, dizziness
- Photosensitivity (sun sensitivity rash)
- Mild blurred vision early in treatment as glucose levels shift
Serious but Less Common Side Effects
- Prolonged or severe hypoglycemia, often requiring hospital observation overnight
- Cholestatic jaundice and hepatitis (rare)
- Hemolytic anemia in G6PD deficiency
- Skin rashes including erythema multiforme
- Hyponatremia (uncommon)
- Disulfiram-like reaction with alcohol (rare with glyburide; more common with older first-generation sulfonylureas)
Why the Beers Criteria Flag Glyburide
The American Geriatrics Society 2023 Beers Criteria list glyburide as a medication to avoid in adults 65 and older because of high risk of severe and prolonged hypoglycemia. Comparative studies show roughly twice the hypoglycemia rate of glipizide in older patients. The active metabolites accumulate as kidney function declines, which is nearly universal with age. Hospitalizations for sulfonylurea-related hypoglycemia in older adults are predominantly from glyburide, not glipizide or glimepiride.
Glyburide Compared to Other Sulfonylureas
| Drug | A1C Drop | Hypoglycemia Risk | Active Metabolites | Older-Adult Use |
|---|---|---|---|---|
| Glyburide | 1.0 to 1.5% | Highest in class | Yes — long half-life | Beers — avoid |
| Glipizide | 1.0 to 1.5% | Moderate | None important | Preferred SU if needed |
| Glimepiride | 1.0 to 1.5% | Moderate, possibly lower | Minor, weakly active | Acceptable with caution |
| Gliclazide (non-US) | 1.0 to 1.5% | Lowest in class (MR form) | None important | Preferred where available |
Drug Interactions
- Beta-blockers — mask hypoglycemia symptoms
- Fluconazole, sulfa antibiotics, gemfibrozil — raise glyburide levels
- NSAIDs, salicylates — augment hypoglycemic effect
- Corticosteroids, thiazide diuretics — oppose hypoglycemic effect
- Bosentan — contraindicated combination (hepatotoxicity)
- Alcohol — increases hypoglycemia risk
- Warfarin — protein-binding interaction
Who Should Avoid Glyburide
- Adults 65 and older — use glipizide or glimepiride instead
- eGFR below 60 mL/min — metabolite accumulation
- Significant liver disease
- Sulfonylurea or sulfonamide allergy (history of severe reaction)
- Type 1 diabetes or DKA
- Pregnancy (insulin preferred under modern guidance)
- Frequent meal-skippers, heavy alcohol use, or prior severe hypoglycemia
- Concurrent bosentan
Modern Positioning
The ADA Standards of Care 2024 no longer recommend any sulfonylurea as preferred first-line add-on to metformin when newer drug classes are accessible. Within the class, glipizide and glimepiride are preferred over glyburide because of better hypoglycemia profiles. Glyburide is rarely the right choice in modern US practice unless cost is the dominant factor and a safer sulfonylurea is unavailable.
Living with Glyburide
- Take with breakfast, not on an empty stomach
- Never skip a meal after dosing
- Carry fast-acting glucose at all times
- Test glucose 4 times daily during titration
- Tell every clinician about the medication before new prescriptions or imaging with contrast
- Avoid heavy or fasting alcohol
- Stop and call clinician for jaundice, dark urine, or repeated low-glucose events
Related Reading
See our companion guides on glipizide, glimepiride, and class-level sulfonylureas side effects. The broader treatment overview and is prediabetes reversible guide give context for where sulfonylureas fit relative to lifestyle and other medications.
The Bottom Line
Glyburide still works — A1C drops of 1 to 1.5 percent are real, and the drug is among the cheapest available. But its long-acting metabolites cause more frequent and longer-lasting hypoglycemia than glipizide or glimepiride, and the Beers criteria specifically flag glyburide as potentially inappropriate for adults 65 and older. Avoid it in significant kidney disease, frequent meal-skipping, heavy alcohol use, or prior severe hypoglycemia. Most US guidelines now place sulfonylureas behind metformin, GLP-1 agonists, and SGLT2 inhibitors, and within the class glyburide ranks behind its safer cousins. Talk to your clinician about whether a switch to glipizide or another option may fit your situation better.
